{"id":"al3818-capsule","safety":{"commonSideEffects":[{"rate":null,"effect":"Diarrhea"},{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Hypertension"},{"rate":null,"effect":"Anorexia"}]},"_chembl":{"chemblId":"CHEMBL5572229","moleculeType":null,"molecularWeight":"443.91"},"_fixedAt":"2026-03-30T16:07:42.981754","_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"AL3818 inhibits several key kinases including FGFR, VEGFR, and other receptor tyrosine kinases that drive tumor cell proliferation and promote new blood vessel formation. By blocking these pathways, the drug aims to suppress tumor growth and limit the blood supply to cancer cells. This multi-targeted approach is designed to provide anti-tumor and anti-angiogenic activity.","oneSentence":"AL3818 is a tyrosine kinase inhibitor that targets multiple receptor tyrosine kinases involved in tumor growth and angiogenesis.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T01:00:26.010Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Advanced or metastatic solid tumors (Phase 3 development)"}]},"_fixedFields":["pubmed(10)"],"trialDetails":[{"nctId":"NCT06897579","phase":"PHASE2","title":"Carboplatin/Cisplatin + Etoposide + Benmelstobart Sequential Benmelstobart Combined With Anlotinib Versus Carboplatin/Cisplatin + Etoposide + Tislelizumab Sequential Tislelizumab in the Treatment of Extensive Stage Small Cell Lung Cancer","status":"RECRUITING","sponsor":"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","startDate":"2025-04-07","conditions":"Extensive Stage Small Cell Lung Cancer","enrollment":134},{"nctId":"NCT07446335","phase":"PHASE3","title":"A Phase III Study of First-line Anlotinib Combined With Benmelstobart in Patients With Advanced Esophageal Squamous Cell Carcinoma","status":"NOT_YET_RECRUITING","sponsor":"The First Affiliated Hospital of Zhengzhou University","startDate":"2026-04","conditions":"Advanced Esophageal Squamous Cell Carcinoma","enrollment":578},{"nctId":"NCT07438886","phase":"PHASE1","title":"Catequentinib Hydrochloride (AL3818) Drug-Drug Interaction Study in Healthy Volunteers","status":"NOT_YET_RECRUITING","sponsor":"Advenchen Laboratories Nanjing Ltd.","startDate":"2026-03-02","conditions":"Healthy Volunteer","enrollment":16},{"nctId":"NCT03016819","phase":"PHASE3","title":"Phase III Trial of Anlotinib, Catequentinib in Advanced Alveolar Soft Part Sarcoma, Leiomyosarcoma, Synovial Sarcoma (APROMISS)","status":"RECRUITING","sponsor":"Advenchen Laboratories, LLC","startDate":"2017-08-15","conditions":"Alveolar Soft Part Sarcoma, Leiomyosarcoma, Synovial Sarcoma","enrollment":325},{"nctId":"NCT05828953","phase":"PHASE2, PHASE3","title":"Anlotinib Capsules in the Treatment for IPF/PF-ILDs","status":"RECRUITING","sponsor":"First Affiliated Hospital of Wenzhou Medical University","startDate":"2021-09-28","conditions":"Interstitial Lung Diseases","enrollment":30},{"nctId":"NCT05685550","phase":"PHASE2","title":"Safety and Efficacy Analysis of Oral Etoposide Combined With Anlotinib and Envafolimab in First-line Treatment of Elderly Patients With Small Cell Lung Cancer/ Open-label, Single-arm, Exploratory Phase II Clinical Study","status":"ACTIVE_NOT_RECRUITING","sponsor":"Tianjin Medical University Cancer Institute and Hospital","startDate":"2023-04-12","conditions":"Progression Free Survival(PFS)","enrollment":30},{"nctId":"NCT07385079","phase":"PHASE3","title":"Anlotinib Plus Immunotherapy and Chemoradiotherapy for High-Risk Nasopharyngeal Carcinoma","status":"NOT_YET_RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2026-03-01","conditions":"Nasopharyngeal Cancinoma (NPC), Nasopharyngeal Cancer","enrollment":412},{"nctId":"NCT04854668","phase":"PHASE3","title":"A Study of Anlotinib Hydrochloride Capsule Combined With Chemotherapy as First-line Treatment in Subjects With RAS/BRAF Wild Metastatic Colorectal Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","startDate":"2021-05-27","conditions":"Metastatic Colorectal Cancer","enrollment":748},{"nctId":"NCT07355855","phase":"PHASE2","title":"A Clinical Study on the Efficacy and Safety of All-trans Retinoic Acid Combined With VAC Regimen in the Treatment of Intermediate-to-high-risk Rhabdomyosarcoma","status":"NOT_YET_RECRUITING","sponsor":"Fudan University","startDate":"2026-01","conditions":"Rhabdomyosarcoma","enrollment":106},{"nctId":"NCT07330544","phase":"PHASE2","title":"A Phase II Clinical Study Evaluating Entinostat With or Without Anlotinib + Fulvestrant for the Treatment of Hormone Receptor (HR) -Positive, Human Epidermal Growth Factor Receptor-2 (HER-2) -Negative Advanced Breast Cancer That Relapsed or Progressed After Endocrine Therapy","status":"RECRUITING","sponsor":"Zhejiang Cancer Hospital","startDate":"2025-11-24","conditions":"Breast Cancer","enrollment":118},{"nctId":"NCT05481645","phase":"PHASE2","title":"Efficacy and Safety of TQB2450 Injection Combined With Chemotherapy ± Anlotinib Hydrochloride Capsules for Advanced Endometrial Cancer or Sarcoma of Uterus.","status":"TERMINATED","sponsor":"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","startDate":"2022-08-26","conditions":"Advanced Endometrial Cancer, Sarcoma of Uterus","enrollment":71},{"nctId":"NCT07165951","phase":"PHASE3","title":"Clinical Trial Comparing TQB2868 Injection Combined With Anlotinib Hydrochloride Capsules With Placebo Combined With Chemotherapy as First-line Treatment for Metastatic Pancreatic Ductal Adenocarcinoma (mPDAC)","status":"RECRUITING","sponsor":"Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.","startDate":"2025-12-02","conditions":"Metastatic Pancreatic Ductal Adenocarcinoma","enrollment":566},{"nctId":"NCT06438783","phase":"PHASE1","title":"TQB2928 Injection Combined Anlotinib Hydrochloride Capsule in Recurrent/Metastatic Osteosarcoma and Other Solid Tumors","status":"TERMINATED","sponsor":"Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.","startDate":"2024-02-15","conditions":"Osteosarcoma, Other Solid Tumors","enrollment":20},{"nctId":"NCT06352008","phase":"PHASE2","title":"To Evaluate the Efficacy and Safety of Anlotinib Hydrochloride Capsule in Postoperative Non-pCR Patients With Non-small Cell Lung Cancer","status":"RECRUITING","sponsor":"Tianjin Medical University Cancer Institute and Hospital","startDate":"2024-07-01","conditions":"Non-Small Cell Lung Cancer","enrollment":64},{"nctId":"NCT06970145","phase":"PHASE1, PHASE2","title":"Safety and Efficacy of Anlotinib in the Treatment of Recurrent Craniopharyngioma","status":"RECRUITING","sponsor":"Nanfang Hospital, Southern Medical University","startDate":"2025-04-25","conditions":"Craniopharyngiomas","enrollment":57},{"nctId":"NCT07153887","phase":"PHASE2","title":"Vebreltinib for Advanced or Metastatic CCS","status":"RECRUITING","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","startDate":"2025-09-30","conditions":"Clear Cell Sarcoma (CCS)","enrollment":30},{"nctId":"NCT06767813","phase":"PHASE2","title":"Clinical Study of TQB2868 Injection Combined With Anlotinib Capsule and Chemotherapy in the First-line Treatment of Metastatic Pancreatic Neoplasms","status":"RECRUITING","sponsor":"Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.","startDate":"2024-03-19","conditions":"Pancreatic Neoplasms","enrollment":80},{"nctId":"NCT07137884","phase":"PHASE2","title":"Anlotinib Hydrochloride Capsules in Maintenance Treatment for Intermediate-High Risk Rhabdomyosarcoma in Children","status":"NOT_YET_RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2025-10-01","conditions":"Rhabdomyosarcoma Recurrent, Maintenance Treatment","enrollment":150},{"nctId":"NCT05975645","phase":"PHASE1","title":"A Clinical Study of TQB2618 Injection Combined With Penpulimab Injection and Anlotinib Hydrochloride Capsules for First-line Treatment of Advanced Hepatocellular Carcinoma (HCC).","status":"TERMINATED","sponsor":"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","startDate":"2023-08-15","conditions":"Advanced Hepatocellular Carcinoma","enrollment":29},{"nctId":"NCT06379087","phase":"PHASE2","title":"Radiation Therapy Followed by Tislelizumab and Anlotinib Aeoadjuvant/Adjuvant Therapy for Stage II-IIIA NSCLC","status":"RECRUITING","sponsor":"Ji Yongling","startDate":"2024-05-01","conditions":"Non-Small Cell Lung Cancer","enrollment":20},{"nctId":"NCT04574284","phase":"PHASE2","title":"A Study of TQB2450 Injection Combined With Anlotinib Hydrochloride Capsule in Subjects With Advanced Endometrial Cancer","status":"COMPLETED","sponsor":"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","startDate":"2020-09-29","conditions":"Advanced Endometrial Cancer","enrollment":170},{"nctId":"NCT04671303","phase":"PHASE2","title":"To Evaluate the Efficacy and Safety of Anlotinib Combined With Furmonertinib Mesylate in Lung Cancer","status":"COMPLETED","sponsor":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","startDate":"2021-01-01","conditions":"Lung Cancer","enrollment":36},{"nctId":"NCT06429397","phase":"PHASE2","title":"Anlotinib Combined With Benmelstobart for Advanced Pheochromocytoma","status":"NOT_YET_RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2025-05-01","conditions":"Pheochromocytoma","enrollment":22},{"nctId":"NCT06931145","phase":"PHASE4","title":"Benmelstobart, Anlotinib and Chemotherapy as First-line Treatment for Extensive-stage Small-cell Lung Cancer","status":"NOT_YET_RECRUITING","sponsor":"Peking Union Medical College Hospital","startDate":"2025-04-15","conditions":"Extensive-stage Small Cell Lung Cancer","enrollment":50},{"nctId":"NCT06886347","phase":"PHASE1","title":"Metastatic Nasopharyngeal Carcinoma","status":"RECRUITING","sponsor":"Chen Xiaozhong","startDate":"2023-07-07","conditions":"Metastatic Nasopharyngeal Carcinoma","enrollment":47},{"nctId":"NCT04165330","phase":"PHASE1, PHASE2","title":"Evaluation of AL3818 in Combination With Nivolumab in Solid Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sarcoma Oncology Research Center, LLC","startDate":"2019-10-17","conditions":"Solid Tumor, Adult, Soft Tissue Sarcoma, Non Small Cell Lung Cancer","enrollment":56},{"nctId":"NCT04344158","phase":"PHASE3","title":"A Phase III Clinical Trial of AK105 Injection Combined With Anlotinib Hydrochloride Capsules Versus Sorafenib in Subjects With Advanced Hepatocellular Carcinoma (HCC)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","startDate":"2020-08-11","conditions":"Advanced Hepatocellular Carcinoma (HCC)","enrollment":648},{"nctId":"NCT05021328","phase":"PHASE1","title":"Toripalimab Combined With Anlotinib and SBRT in Patients With Untreated Brain Metastases of Driven Gene-negative NSCLC","status":"COMPLETED","sponsor":"Hubei Cancer Hospital","startDate":"2021-10-01","conditions":"NSCLC","enrollment":13},{"nctId":"NCT05214222","phase":"PHASE2","title":"Penpulimab Plus Chemotherapy With/Without Anlotinib for Patients With Advanced Esophageal Squamous Cell Carcinoma","status":"RECRUITING","sponsor":"Nanfang Hospital, Southern Medical University","startDate":"2022-09-02","conditions":"Advanced Esophageal Squamous Cell Carcinoma","enrollment":100},{"nctId":"NCT06739395","phase":"PHASE2","title":"Precision Medicine Trial Based on Molecular Matching Therapy for Patients With Standard Treatment Exhaustion","status":"RECRUITING","sponsor":"Tianjin Medical University Second Hospital","startDate":"2024-11-01","conditions":"Solid Tumor, Precision Medicine","enrollment":300},{"nctId":"NCT06660511","phase":"EARLY_PHASE1","title":"Exploratory Study on the Safety and Efficacy of Disitamab Vedotin in Combination with Anlotinib Hydrochloride for the Treatment of HER-2-expressing Recurrent Platinum-resistant Ovarian Cancer.","status":"RECRUITING","sponsor":"Second Xiangya Hospital of Central South University","startDate":"2024-10-15","conditions":"Ovarian Cancer Recurrent","enrollment":5},{"nctId":"NCT06611657","phase":"PHASE2","title":"Antirotinib Hydrochloride Plus Whole Brain Radiotherapy for Small Cell Lung Cancer With Brain Metastases","status":"ACTIVE_NOT_RECRUITING","sponsor":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","startDate":"2021-08-20","conditions":"Whole Brain Radiotherapy","enrollment":40},{"nctId":"NCT04523272","phase":"PHASE3","title":"A Study of TQB2450 Injection Combined With Anlotinib Hydrochloride Capsule Versus Sunitinib in Subjects With Advanced Renal Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","startDate":"2020-08-25","conditions":"Advanced Renal Cancer","enrollment":528},{"nctId":"NCT06141226","phase":"PHASE2","title":"Phase II Clinical Trial to Evaluate the Safety and Efficacy of TQB2450 Injection Combined With Anlotinib Capsule and Chemotherapy in the Treatment of Immunoresistant Advanced Non-small Cell Lung Cancer","status":"RECRUITING","sponsor":"Tianjin Medical University Cancer Institute and Hospital","startDate":"2023-04-12","conditions":"Non-small-cell Lung Cancer","enrollment":148},{"nctId":"NCT06507891","phase":"PHASE1, PHASE2","title":"A Clinical Study to Evaluate the Tolerance, Pharmacokinetics and Efficacy of TQ-A3334 Tablets","status":"TERMINATED","sponsor":"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","startDate":"2020-07-06","conditions":"Non Small Cell Lung Cancer","enrollment":30},{"nctId":"NCT06469879","phase":"PHASE3","title":"A Clinical Study of TQB2450 Combined With Anlotinib in Limited-Stage Small Cell Lung Cancer Patients","status":"NOT_YET_RECRUITING","sponsor":"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","startDate":"2024-09","conditions":"Small Cell Lung Cancer Limited Stage","enrollment":358},{"nctId":"NCT06475599","phase":"PHASE3","title":"Anlotinib Hydrochloride Capsules Combined With TQB2450 in the Treatment of Endometrial Cancer","status":"NOT_YET_RECRUITING","sponsor":"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","startDate":"2024-07","conditions":"Endometrial Cancer","enrollment":420},{"nctId":"NCT06341530","phase":"PHASE2","title":"Anlotinib Combined With Penpulimab as Front-line Treatment in Advanced Non-small Cell Lung Cancer","status":"RECRUITING","sponsor":"The First Affiliated Hospital of Zhengzhou University","startDate":"2024-01-31","conditions":"Non-small Cell Lung Cancer","enrollment":33},{"nctId":"NCT06327698","phase":"PHASE2","title":"Cadonilimab in Combination With Anlotinib in the Treatment of Locally Progressive or Metastatic Melanoma With First-Line Therapy Failure","status":"NOT_YET_RECRUITING","sponsor":"Hunan Cancer Hospital","startDate":"2024-05-15","conditions":"Melanoma","enrollment":30},{"nctId":"NCT06320301","phase":"PHASE2","title":"Adebrelimab and a TKI in Combination With GEMOX in First-line Treatment of Advanced Biliary Tract Cancers (BTC)","status":"RECRUITING","sponsor":"Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University","startDate":"2024-04-01","conditions":"Biliary Tract Cancer, Gemox Chemotherapy","enrollment":43},{"nctId":"NCT06222944","phase":"PHASE2","title":"Anlotinib, TQB2450 (PD-L1 Inhibitor), and Albumin-bound Paclitaxel Regimens in the Treatment of GC/GEJA","status":"NOT_YET_RECRUITING","sponsor":"Peking University","startDate":"2024-02-25","conditions":"Gastric Cancer, Adenocarcinoma of Esophagogastric Junction","enrollment":90},{"nctId":"NCT06010901","phase":"PHASE1","title":"A Clinical Study of TQB2618 Injection Monotherapy and Combination Regimen (With Penpulimab Injection ±Anlotinib Hydrochloride Capsules) in the Four or Later Lines of Treatment of Advanced Colorectal Cancer.","status":"UNKNOWN","sponsor":"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","startDate":"2024-01-13","conditions":"Colorectal Cancer","enrollment":75},{"nctId":"NCT05028504","phase":"PHASE2","title":"A Phase II Study of Anlotinib Combined With Penpulimab in Subjects With Gynecological Cancer","status":"UNKNOWN","sponsor":"Sichuan Cancer Hospital and Research Institute","startDate":"2022-05-10","conditions":"Gynecological Cancer","enrollment":86},{"nctId":"NCT05193604","phase":"PHASE1","title":"A Clinical Trial to Evaluate Tolerability and Security of TQB2858 Injection in Subjects With Advanced Pancreatic Carcinoma","status":"TERMINATED","sponsor":"Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.","startDate":"2022-03-24","conditions":"Pancreatic Carcinoma","enrollment":29},{"nctId":"NCT05494060","phase":"PHASE2","title":"XELOX Combined With Anlotinib and Penpulimab vs XELOX as Adjuvant Therapy in ctDNA Positive Gastric and Esophagogastric Junction Adenocarcinoma","status":"RECRUITING","sponsor":"The First Affiliated Hospital with Nanjing Medical University","startDate":"2022-03-16","conditions":"Carcinoma, Gastrointestinal Diseases, Stomach Cancer","enrollment":80},{"nctId":"NCT06102928","phase":"NA","title":"A Clinical Study of the Combination of Anlotinib and Aumolertinib in the First-line Treatment of Advanced NSCLC With EGFR 21L858R Mutation","status":"RECRUITING","sponsor":"Kunming Medical University","startDate":"2023-10-30","conditions":"Non-Small Cell Lung Cancer With Mutation in Epidermal Growth Factor Receptor","enrollment":30},{"nctId":"NCT06062563","phase":"NA","title":"Study of Anlotinib in Patients With Radioiodine Refractory Differentiated Thyroid Cancer","status":"UNKNOWN","sponsor":"Peking Union Medical College Hospital","startDate":"2023-11-11","conditions":"Locally Advanced or Metastatic Radioiodine-refractory Differentiated Thyroid Carcinoma","enrollment":10},{"nctId":"NCT04119674","phase":"PHASE1, PHASE2","title":"Pilot Study of Anlotinib With STUPP Regimen for Patients With Newly Diagnosed Glioblastoma","status":"COMPLETED","sponsor":"Zhejiang Cancer Hospital","startDate":"2019-03-19","conditions":"Glioblastoma","enrollment":33},{"nctId":"NCT05996484","phase":"PHASE2","title":"Neoadjuvant Therapy of Anlotinib Combined With Toripalimab and Chemotherapy for Resectable Esophageal Carcinoma","status":"NOT_YET_RECRUITING","sponsor":"Nanfang Hospital, Southern Medical University","startDate":"2023-09","conditions":"Esophageal Carcinoma, Neoadjuvant Therapy","enrollment":25},{"nctId":"NCT05994365","phase":"","title":"Study of Anlotinib Hydrochloride Capsules in the Treatment of Locally Advanced or Metastatic Radioiodine-Refractory Differentiated Thyroid Carcinoma","status":"RECRUITING","sponsor":"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","startDate":"2023-08","conditions":"Thyroid Neoplasms","enrollment":380},{"nctId":"NCT05830500","phase":"PHASE4","title":"Study of Anlotinib in Patients With Advanced Medullary Thyroid Carcinoma","status":"RECRUITING","sponsor":"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","startDate":"2023-06-19","conditions":"Medullary Thyroid Cancer","enrollment":360},{"nctId":"NCT05942508","phase":"PHASE1","title":"A Phase Ib Study of TQB2450 Combined With Anlotinib in Patients With Limited Stage Small Cell Lung Cancer After First-line Radiotherapy and Chemotherapy","status":"UNKNOWN","sponsor":"Jinming Yu","startDate":"2023-05-30","conditions":"Limited Stage Small Cell Lung Cancer, Not Progressed After First-line Chemoradiotherapy","enrollment":20},{"nctId":"NCT05913089","phase":"PHASE2","title":"A Clinical Study of TQB2450 Injection Combined With Chemotherapy or Anlotinib Hydrochloride Capsule in the Treatment of Non Small Cell Lung Cancer","status":"RECRUITING","sponsor":"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","startDate":"2023-06-14","conditions":"Non Small Cell Lung Cancer","enrollment":58},{"nctId":"NCT05038813","phase":"PHASE2","title":"Anlotinib Combined With TQB2450 (PD-L1 Inhibitor) in the Treatment of Advanced Esophageal Squamous Cell Carcinoma(ESCC)","status":"UNKNOWN","sponsor":"The First Affiliated Hospital of Zhengzhou University","startDate":"2022-03-14","conditions":"Esophageal Squamous Cell Carcinoma","enrollment":46},{"nctId":"NCT05862337","phase":"PHASE3","title":"Anlotinib Hydrochloride Capsules Combined With Penpulimab Injection for the Treatment of Hepatocellular Carcinoma at High Risk of Recurrence.","status":"RECRUITING","sponsor":"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","startDate":"2023-05-10","conditions":"Hepatocellular Carcinoma","enrollment":480},{"nctId":"NCT05736952","phase":"PHASE2","title":"Oral Topotecan Combined With Anlotinib in Patients With Platinum-resistant Recurrent Ovarian Cancer","status":"WITHDRAWN","sponsor":"Xinhua Hospital, Shanghai Jiao Tong University School of Medicine","startDate":"2023-03-01","conditions":"Platinum-resistant Ovarian Cancer","enrollment":""},{"nctId":"NCT05800080","phase":"NA","title":"An Exploratory Study of Immunotherapy Combined With Anlotinib and Chemotherapy in Perioperative Treatment of LAGC","status":"UNKNOWN","sponsor":"Xijing Hospital","startDate":"2023-04","conditions":"Gastric Cancer","enrollment":114},{"nctId":"NCT04438902","phase":"PHASE2","title":"Osimertinib Combined With Anlotinib in EGFR T790M Mutated NSCLC Patients With Progression on Osimertinib Treatment","status":"TERMINATED","sponsor":"First Affiliated Hospital of Zhejiang University","startDate":"2020-12-12","conditions":"Non Small Cell Lung Cancer","enrollment":3},{"nctId":"NCT05718167","phase":"PHASE3","title":"TQB2450 Injection Combined With Chemotherapy Followed by Sequential Combination With Anlotinib Hydrochloride Capsule for First-line Treatment of Advanced Squamous Non-small Cell Lung Cancer.","status":"UNKNOWN","sponsor":"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","startDate":"2023-02","conditions":"Advanced Squamous Non-Small Cell Lung Carcinoma","enrollment":570},{"nctId":"NCT05252078","phase":"PHASE2","title":"Anlotinib Hydrochloride Capsules Combined With TQB2450 Injection in Esophageal Squamous Cell Carcinoma Patients","status":"RECRUITING","sponsor":"Jiangxi Provincial Cancer Hospital","startDate":"2022-06-02","conditions":"Esophageal Squamous Cell Carcinoma, Esophageal Neoplasms, Esophageal Diseases","enrollment":30},{"nctId":"NCT05608785","phase":"PHASE1, PHASE2","title":"Single-center, Multi-cohort Exploratory Phase Ib/II Clinical Study of First-line Treatment of Unresectable Locally Advanced/Advanced Adenocarcinoma of the Stomach or Gastroesophageal Junction Based on Different Genotypes","status":"UNKNOWN","sponsor":"Henan Cancer Hospital","startDate":"2023-01-01","conditions":"Gastric Cancer, Gastroesophageal-junction Cancer","enrollment":45},{"nctId":"NCT05559242","phase":"PHASE1","title":"Pharmacokinetic Study of Anlotinib Hydrochloride Capsules in Healthy Subjects and Liver Dysfunction Patients","status":"UNKNOWN","sponsor":"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","startDate":"2022-10","conditions":"Liver Dysfunction","enrollment":30},{"nctId":"NCT05549973","phase":"PHASE1","title":"Anlotinib Hydrochloride Capsule Monotherapy and Combination Therapy Relapsed and Refractory Multiple Myeloma","status":"UNKNOWN","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2022-09","conditions":"Multiple Myeloma","enrollment":32},{"nctId":"NCT05485350","phase":"PHASE2","title":"Anlotinib , Penpulimab Combined With SBRT for Metastatic Non-Small Cell Lung Cancer (NSCLC)","status":"UNKNOWN","sponsor":"Peking University Third Hospital","startDate":"2022-09-12","conditions":"Non-Small Cell Lung Cancer","enrollment":32},{"nctId":"NCT04080843","phase":"PHASE2","title":"Anlotinib Hydrochloride Capsules Combined With CAPEOX in RAS and BRAF Wild-type mCRC Patients","status":"COMPLETED","sponsor":"Zhejiang University","startDate":"2019-11-15","conditions":"Colorectal Cancer, RAS and BRAF Wild-type, Colorectal Neoplasms","enrollment":30},{"nctId":"NCT05244993","phase":"PHASE2","title":"AK105 Plus Anlotinib Hydrochloride Combined With Albumin Paclitaxel as a First-line Therapy in Patients With Advanced Triple-negative Breast Cancer","status":"UNKNOWN","sponsor":"Liaoning Cancer Hospital & Institute","startDate":"2022-07","conditions":"Breast Neoplasm Female","enrollment":42},{"nctId":"NCT04772001","phase":"NA","title":"Concurrent Radiochemotherapy Plus Anlotinib for Locally Advanced Cervical Cancer","status":"UNKNOWN","sponsor":"Zhongnan Hospital","startDate":"2021-03-12","conditions":"Uterine Cervical Neoplasms, Chemoradiotherapy, Angiogenesis","enrollment":53},{"nctId":"NCT05111366","phase":"PHASE2","title":"TQB2450 Plus Anlotinib as Adjuvant Therapy in HCC Patients at High Risk of Recurrence After Resection","status":"UNKNOWN","sponsor":"Xianhai Mao","startDate":"2022-01-06","conditions":"Hepatocellular Carcinoma, Adjuvant Therapy","enrollment":37},{"nctId":"NCT05346952","phase":"PHASE3","title":"A Study of TQB2450 Injection Plus Chemotherapy Followed by TQB2450 Plus Anlotinib Versus Tislelizumab Plus Chemotherapy Followed by Tislelizumab in the Treatment of First-line Non-squamous Non-small Cell Lung Cancer(NSCLC).","status":"UNKNOWN","sponsor":"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","startDate":"2022-01-25","conditions":"Advanced Non-squamous Non-small Cell Lung Cancer","enrollment":390},{"nctId":"NCT04325763","phase":"PHASE3","title":"A Study of TQB2450 in Subjects With Stage III Non-Small Cell Lung Cancer(NSCLC)","status":"UNKNOWN","sponsor":"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","startDate":"2020-05-27","conditions":"Stage III Non-small-cell Lung Cancer","enrollment":315},{"nctId":"NCT04223583","phase":"PHASE4","title":"Study on the Treatment of Soft Tissue Sarcoma With First-line Chemotherapy Failure by Anrotenil Hydrochloride Capsule","status":"COMPLETED","sponsor":"Henan Cancer Hospital","startDate":"2019-06-26","conditions":"Soft Tissue Sarcomas","enrollment":70},{"nctId":"NCT04958993","phase":"PHASE1, PHASE2","title":"A Trial of Anlotinib Combined With Concurrent Chemoradiotherapy in Patients With Unresectable Stage III Non-small Cell Lung Cancer","status":"TERMINATED","sponsor":"Shandong Cancer Hospital and Institute","startDate":"2020-11-12","conditions":"Non-small Cell Lung Cancer","enrollment":7},{"nctId":"NCT05121350","phase":"PHASE3","title":"A Clinical Trial to Evaluate the Efficacy and Safety of Anotinib Hydrochloride Capsule Combined With Epirubicin Hydrochloride Versus Placebo Combined With Epirubicin Hydrochloride in First-line Treatment of Advanced Soft Tissue Sarcoma","status":"UNKNOWN","sponsor":"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","startDate":"2022-03","conditions":"Soft Tissue Sarcoma","enrollment":256},{"nctId":"NCT05198531","phase":"PHASE1, PHASE2","title":"To Evaluate the Safety and Efficacy of TQB2858 Injection to the Subjects With Recurrent/Metastatic Nasopharyngeal Cancer","status":"UNKNOWN","sponsor":"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","startDate":"2022-01","conditions":"Recurrent / Metastatic Nasopharyngeal Cancer","enrollment":90},{"nctId":"NCT05089643","phase":"PHASE2","title":"Anrotinib in Combination With Capecitabine in Advanced Triple Negative Breast Cancer","status":"UNKNOWN","sponsor":"Chinese Academy of Medical Sciences","startDate":"2019-04-11","conditions":"Metastatic Triple-Negative Breast Cancer","enrollment":35},{"nctId":"NCT05145218","phase":"PHASE3","title":"A Clinical Study of TQB2450 Injection Combined With Anlotinib Hydrochloride Capsules Versus Paclitaxel as Weekly Treatment of Relapsed Platinum-resistant Ovarian Cancer","status":"UNKNOWN","sponsor":"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","startDate":"2021-09-28","conditions":"Recurrent Platinum-resistant Ovarian Cancer","enrollment":405},{"nctId":"NCT05121363","phase":"PHASE2","title":"A Clinical Trial to Evaluate TQB2858 Injection Combined With Anlotinib Hydrochloride Capsule in the Treatment of Recurrent or Metastatic Advanced Endometrial Carcinoma","status":"UNKNOWN","sponsor":"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","startDate":"2021-12","conditions":"Endometrial Carcinoma","enrollment":113},{"nctId":"NCT05133349","phase":"PHASE2","title":"A Prospective Phase II Efficacy and Safety Study of Anlotinib in Metastatic or Locally Advanced Pheochromocytoma/ Paraganglioma : Open-label Single-arm, Exploratory Trial","status":"UNKNOWN","sponsor":"Nanjing First Hospital, Nanjing Medical University","startDate":"2021-09-14","conditions":"Advanced or Metastatic Paraganglioma/ Pheochromocytoma","enrollment":20},{"nctId":"NCT05124431","phase":"PHASE2","title":"Anlotinib Plus Everolimus as First-line Treatment for Advanced Non Clear Cell Renal Cell Carcinoma","status":"UNKNOWN","sponsor":"Fudan University","startDate":"2021-12","conditions":"Renal Cell Carcinoma","enrollment":30},{"nctId":"NCT05087602","phase":"PHASE2","title":"Toripalimab Combined With Anlotinib in Unresectable Locally Advanced or Metastatic Acral Malignant Melanoma","status":"UNKNOWN","sponsor":"Qilu Hospital of Shandong University","startDate":"2021-11-01","conditions":"Locally Advanced or Metastatic Acral Malignant Melanoma","enrollment":29},{"nctId":"NCT05068206","phase":"PHASE2","title":"A Clinical Study to Compare the Efficacy and Safety of AK105 Plus Anlotinib and Capecitabine/Oxaliplatin (CapeOx) , Anlotinib Plus CapeOx, Bevacizumab Plus CapeOx","status":"UNKNOWN","sponsor":"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","startDate":"2021-10-08","conditions":"Unresectable Metastatic Colorectal Cancer","enrollment":120},{"nctId":"NCT04924192","phase":"PHASE2","title":"A Clinical Study of TQB3616 Capsules Combined With Anlotinib Hydrochloride Capsules or Standard Chemotherapy Second-line and Above in the Treatment of Advanced Lung Cancer","status":"UNKNOWN","sponsor":"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","startDate":"2021-08-18","conditions":"Advanced Lung Carcinoma","enrollment":126},{"nctId":"NCT05035914","phase":"PHASE1, PHASE2","title":"Anlotinib Combined With mXELIRI as Second-line Treatment of Advanced Colorectal Cancer","status":"UNKNOWN","sponsor":"Guangzhou University of Traditional Chinese Medicine","startDate":"2021-07-09","conditions":"Advanced Colorectal Cancer","enrollment":94},{"nctId":"NCT05033587","phase":"PHASE2","title":"Study of AK105 With Anlotinib and Radiotherapy Adjuvant Therapy in MGMT Unmethylated Newly Diagnosed Glioblastoma.","status":"UNKNOWN","sponsor":"The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School","startDate":"2021-09","conditions":"MGMT-Unmethylated Glioblastoma","enrollment":28},{"nctId":"NCT04063683","phase":"PHASE2","title":"Paclitaxel and DDP Combined With Anlotinib in the First-line Treatment for Patients With Advanced Esophageal Squamous Cell Carcinoma（ESCC）.","status":"UNKNOWN","sponsor":"Henan Cancer Hospital","startDate":"2019-10-07","conditions":"Esophageal Squamous Cell Carcinoma","enrollment":47},{"nctId":"NCT04964479","phase":"PHASE3","title":"A Clinical Study of TQB2450 Injection Combined With Anlotinib Hydrochloride Capsules Versus K Drug in the Treatment of First-line Non-small Cell Lung Cancer(NSCLC)","status":"UNKNOWN","sponsor":"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","startDate":"2021-08-06","conditions":"Non Small Cell Lung Cancer","enrollment":375},{"nctId":"NCT04888546","phase":"PHASE1, PHASE2","title":"TQB2450 Combined With Anlotinib Hydrochloride in the Perioperative Treatment of Hepatocellular Carcinoma Hydrochloride Neoadjuvant Therapy for Resectable Hepatocellular Carcinoma With a High Risk of Recurrence or Metastasis","status":"UNKNOWN","sponsor":"Chinese Academy of Medical Sciences","startDate":"2021-04-30","conditions":"Patients With Resectable Hepatocellular Carcinoma Who Are at High Risk of Recurrence or Metastasi","enrollment":20},{"nctId":"NCT04827004","phase":"PHASE2","title":"A Study of Anlotinib Hydrochloride Capsules in Subjects With Diffuse Large B-Cell Lymphoma","status":"UNKNOWN","sponsor":"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","startDate":"2021-04","conditions":"Diffuse Large B-cell Lymphoma","enrollment":30},{"nctId":"NCT04813406","phase":"NA","title":"Study of Anlotinib Plus Sintilimab in the Treatment of Advanced Esophageal Squamous Cell Carcinoma","status":"UNKNOWN","sponsor":"Henan Provincial People's Hospital","startDate":"2021-03","conditions":"Esophageal Squamous Cell Carcinoma","enrollment":53},{"nctId":"NCT04809142","phase":"PHASE3","title":"A Study of TQB2450 Injection Combined With Anlotinib Hydrochloride Capsule as Second-line Treatment in Subjects With Advanced Biliary Cancer","status":"UNKNOWN","sponsor":"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","startDate":"2021-02-04","conditions":"Advanced Biliary Cancer","enrollment":392},{"nctId":"NCT03736837","phase":"PHASE2","title":"Study of Anlotinib Combined With Icotinib as the First-line Treatment in Patients With EGFR Mutation-positive NSCLC","status":"COMPLETED","sponsor":"Tianjin Medical University Cancer Institute and Hospital","startDate":"2018-12-01","conditions":"Non Small Cell Lung Cancer","enrollment":60},{"nctId":"NCT04731909","phase":"NA","title":"Toripalimab Combined With Anlotinib, Etoposide and Platinum in the Treatment of Extensive-stage Small Cell Lung Cancer","status":"UNKNOWN","sponsor":"Third Military Medical University","startDate":"2018-10-01","conditions":"SCLC, Extensive Stage, Lung Cancer, Small Cell Lung Cancer","enrollment":80},{"nctId":"NCT04725214","phase":"PHASE2","title":"Anlotinib Combined With STUPP for MGMT Nonmethylated Glioblastoma","status":"UNKNOWN","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","startDate":"2021-01-15","conditions":"MGMT-Unmethylated Glioblastoma","enrollment":33},{"nctId":"NCT04236362","phase":"PHASE1, PHASE2","title":"A Study of TQB2450 Combined With Anlotinib in Subjects With Gynecological Cancer","status":"UNKNOWN","sponsor":"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","startDate":"2020-02-27","conditions":"Gynecological Cancer","enrollment":90},{"nctId":"NCT04620837","phase":"PHASE2","title":"Tislelizumab in Combination With Anlotinib With ES-SCLC as Maintenance Therapy After First Line Chemotherapy","status":"UNKNOWN","sponsor":"Chinese Academy of Medical Sciences","startDate":"2020-11-01","conditions":"Small Cell Lung Carcinoma","enrollment":25},{"nctId":"NCT04547855","phase":"PHASE2","title":"Anlotinib Combined With Dose-dense Temozolomide for the First Recurrent or Progressive Glioblastoma After STUPP Regimen","status":"UNKNOWN","sponsor":"Yonggao Mou","startDate":"2020-09-11","conditions":"Glioblastoma","enrollment":54},{"nctId":"NCT04507035","phase":"PHASE4","title":"Treating Locally Advanced Head and Neck Malignant Tumor With Anlotinib and Chemoradiotherapy","status":"UNKNOWN","sponsor":"Sun Yat-sen University","startDate":"2020-09-01","conditions":"Head and Neck Cancer","enrollment":30},{"nctId":"NCT03998085","phase":"NA","title":"Anlotinib Single Drug as the Maintenance Treatment for Advanced NSCLC","status":"UNKNOWN","sponsor":"The First Hospital of Jilin University","startDate":"2019-03-05","conditions":"Non-Small Cell Lung Cancer","enrollment":40},{"nctId":"NCT04273815","phase":"PHASE1, PHASE2","title":"A Study to Evaluate the Tolerance, Pharmacokinetics and Efficacy of TQ-A3334 Tablets","status":"UNKNOWN","sponsor":"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","startDate":"2020-07-06","conditions":"Non-small Cell Lung Cancer","enrollment":40},{"nctId":"NCT04203719","phase":"PHASE2","title":"A Study of Anlotinib and AK105 Injection in Subjects With Advanced Head, Neck and Chest Cancer","status":"UNKNOWN","sponsor":"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","startDate":"2020-05-09","conditions":"Advanced Head, Neck and Chest Cancer","enrollment":140}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":10,"recentPublications":[{"date":"2025 Mar 6","pmid":"40050959","title":"Efficient delivery of anlotinib and radioiodine by long circulating nano-capsules for active enhanced suppression of anaplastic thyroid carcinoma.","journal":"Journal of nanobiotechnology"},{"date":"2024","pmid":"38966063","title":"Desmoplastic small round cell tumor of the kidney: a case report and discussion.","journal":"Frontiers in oncology"},{"date":"2024 Apr 28","pmid":"38678603","title":"Clinical effect of anlotinib in combination with docetaxel in treating advanced non-small cell lung cancer.","journal":"Cellular and molecular biology (Noisy-le-Grand, France)"},{"date":"2024 Mar","pmid":"38142544","title":"Case report of radiotherapy combined with anlotinib and immunotherapy for a patient with esophageal cancer and esophageal fistula.","journal":"Applied radiation and isotopes : including data, instrumentation and methods for use in agriculture, industry and medicine"},{"date":"2023 Oct 31","pmid":"37969289","title":"Etoposide soft capsule combined with anlotinib in the third-line treatment of advanced non-small cell lung cancer: a retrospective cohort study.","journal":"Journal of thoracic disease"}],"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Anlotinib hydrochloride","Catequentenib","Anlotinib","Anlotinib Hydrochloride","Catequentinib"],"phase":"phase_3","status":"active","brandName":"AL3818 Capsule","genericName":"AL3818 Capsule","companyName":"Advenchen Laboratories Nanjing Ltd.","companyId":"advenchen-laboratories-nanjing-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"AL3818 is a tyrosine kinase inhibitor that targets multiple receptor tyrosine kinases involved in tumor growth and angiogenesis. Used for Advanced or metastatic solid tumors (Phase 3 development).","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}